Diagnostics drive Beckman and Biosite but not BD, while cardiovascular device firms are buoyant
This article was originally published in Clinica
Executive Summary
Rochester, New York-based eye care group Bausch & Lomb reported 11% growth in its cataract and vitreoretinal business in the fourth quarter, thanks to double-digit underlying growth in intraocular lens sales. Expansion in phacoemulsification product revenues more than offset a decline in viscoelastics, but refractive surgery revenues were hit by a drop in laser sales in North America.